Safety and Efficacy of Administration of Dl-3-n-butylphthalide for Acute Ischemic Stroke: a Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Trial
Yi‐Cheng Zhu,Liying Cui,Shan Gao,Dongsheng Fan,Jimei Li,Junying Niu,Qing Zhan,Xinyue Qin,Ran Zheng,Kangning Chen,Huadong Zhou,Jinsheng Zeng,Kairun Peng,Zhaohui Zhang,Zuneng Lu,Junjian Zhang,Yumin Liu,Chaodong Zhang,Fang Qu,Bingzhen Cao,Yun Xu,Jiang Wu,Qianqian Wang,Qi Yang,Feng Li,Xingyue Hu,Xiaoping Pan,Zhen‐Ming Chi,Jianzhong Bi,Xinyuan Ding,Kaifu Ke,Weizhen Wang,Wen‐Liang Dong,Hongbin Sun,Ling Li,Wei Wang,Qiang Dong,Li He,Jianping Jia,Yingzhu Chen,Junyan Liu,Bin Peng,Jun Ni,Jia He
DOI: https://doi.org/10.3760/cma.j.issn.1006-7876.2014.02.010
2014-01-01
Abstract:Objective To assess the efficacy and safety of dl-3-n-butylphthalide injection in acute ischemic stroke patients. Methods A randomized, double-blind, double-dummy trial enrolled 552 patients in China, if they were within 48 hours of onset of ischemic stroke, and had a score from 6 to 25 on the National Institutes of Health Stroke Scale (NIHSS). Three hundred and seventy patients were randomly assigned to receive infusion of dl-3-n-butylphthalide and 182 patients received infusion of ozagrel. Results In dl-3-n-butylphthalide group, NIHSS score at baseline, on the 8th and 15th days were 8.64±3.03,6.45±3.88 and 4.71±3.90 respectively, whereas Barthel index score were 45.42±20.82,55.60±25.64 and 65.39±26.85 respectively. The difference of NIHSS score between the 15th day and baseline was significantly higher in dl-3-n-butylphthalide group as compared with ozagrel group (Wilcoxon rank sum test, z=2.21, P=0.027). Similar result was found when Barthel index was evaluated（z=2.50，P=0.012）, suggesting a favorable outcome of dl-3-n-butylphthalide treatment. Among the 515 subjects included in the efficacy analysis, 14 days of treatment with dl-3-n-butylphthalide was significantly associated with a favorable outcome than that in 14-day treatment with ozagrel as measured by NIHSS（z=2.21, P=0.027）and Barthel index (z=2.50, P=0.012). The effective rate on the 15th day was significantly higher in dl-3-n-butylphthalide group as compared with that in ozagrel group. The rate of adverse events was similar between two groups (2.74% vs 4.44%，P=0.34). Elevated alanine aminotransferase was the most common adverse event. Conclusion This trial suggested that the 14-day treatment with dl-3-n-butylphthalide could improve outcomes on the 15th day after stroke, and intravenous administration of dl-3-n-butylphthalide was safety. (Trial registration:Chinese Clinical Trial Registry (ChiCTR-TRC-09000483)). Key words: Brain infarction; Benzofurans; Randomized controlled trial